Key facts
- It has raised $9.9M.
- Notable investors include Mitsubishi UFJ Capital, D.Western Therapeutics Institute, Japan Science And Technology Agency, Kyogin Lease Capital, Kyoto Bank Lease Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ActualEyes
- ·The full record, as it builds
Funding rounds
No funding rounds for ActualEyes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ActualEyes
Developer of regenerative drugs and eye drops intended to treat Fuchs corneal endothelial dystrophy. The company offers a combination of cultured human corneal endothelial cells and an inhibitor for the treatment of bullous keratopathy, enabling healthcare providers to address unmet medical needs and improve outcomes for patients with corneal endothelium disorders.
- Sector
- Healthcare
- HQ
- Kyotanabe, Japan
- Founded
- 2018
- Website
- actualeyes.co.jp/
- Ownership
- Privately Held (backing)
ActualEyes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ActualEyes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ActualEyes in its N-PORT filings yet. We sweep new filings monthly.